Compare BW & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BW | URGN |
|---|---|---|
| Founded | 1867 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 919.9M | 922.1M |
| IPO Year | N/A | 2016 |
| Metric | BW | URGN |
|---|---|---|
| Price | $14.32 | $17.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $7.00 | ★ $29.29 |
| AVG Volume (30 Days) | ★ 5.7M | 796.5K |
| Earning Date | 03-04-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,128,000.00 |
| Revenue This Year | $41.58 | $127.17 |
| Revenue Next Year | $66.70 | $73.82 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.22 | $3.42 |
| 52 Week High | $16.24 | $30.00 |
| Indicator | BW | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 57.32 | 41.03 |
| Support Level | $8.03 | $17.07 |
| Resistance Level | N/A | $20.44 |
| Average True Range (ATR) | 1.61 | 0.87 |
| MACD | 0.06 | -0.05 |
| Stochastic Oscillator | 68.98 | 39.40 |
Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.